Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteogenomic discovery of SARS-CoV-2 neutralizing antibodies
NL-OMON50850Active, not recruiting
- Sponsor
- AbSano
- Start
- Jul 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in coronavirus disease 2019 (COVID-19), sponsored by AbSano. Primary endpoints: Generation of potent anti-SARS-CoV-2 antibodies and Establishment of a rapid monoclonal antibody workflow. Started Jul 2021; status: active, not recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50850.